Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030287 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
A Phase 1 study of Cancer Ovaries and Cancer Peritoneal, sponsored by OncoMed Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 7
- Study locations
NCT03030287 is a Phase 1 study of Cancer Ovaries and Cancer Peritoneal that has completed, run by OncoMed Pharmaceuticals. The registered enrollment target is 44 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT03030287, a Phase 1 study of Cancer Ovaries and Cancer Peritoneal, has completed, sponsored by OncoMed Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the efficacy and safety of an experimental drug, OMP-305B83, when given in combination with paclitaxel. OMP-305B83 is a humanized monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG OMP-305B83
Study Locations (7)
Colorado
- University of Colorado, Anschutz Medical Campus - Aurora
Florida
- H. Lee Moffitt Cancer Center & Research Institute, Inc. (Moffitt Cancer Center) - Tampa
North Carolina
- Levine Cancer Institute - Charlotte
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Pennsylvania
- The University of Pennsylvania Health System - Philadelphia
Tennessee
- Tennessee Oncology, PLLC - Nashville
Texas
- The University of Texas, MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03030287
The ClinicalTrials.gov registry entry for NCT03030287 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cancer Ovaries appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT03030287 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Colorado, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03030287 about?
NCT03030287 is a clinical study titled "A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer". The purpose of this study is to test the efficacy and safety of an experimental drug, OMP-305B83, when given in combination with paclitaxel. OMP-305B83 is a humanized monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may b...
What is the current status of trial NCT03030287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-12. Estimated completion is 2020-04.
What conditions does trial NCT03030287 study?
This clinical trial studies the following conditions: Cancer Ovaries, Cancer Peritoneal, Cancer, Fallopian Tube.
What interventions are being tested in trial NCT03030287?
The interventions under investigation include: Paclitaxel (DRUG), OMP-305B83 (DRUG).
Who is sponsoring clinical trial NCT03030287?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03030287 being conducted?
This trial has 7 study locations across Colorado, Florida, North Carolina, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.